Clinical Trials Browser

Phase 2 × brigatinib × 30 days × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Phase 2 Active not recruiting

NSCLC